LUNG CANCER

BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112

M F Muers¹, R M Rudd², M E R O’Brien³, W Qian⁴, A Hodson⁴, M K B Parmar⁴, D J Girling⁴ on behalf of the British Thoracic Society Mesothelioma Group^*

¹ General Infirmary, Leeds LS1 3EX, UK
² St Bartholomew’s Hospital, London EC1A 7BE, UK
³ Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
⁴ MRC Clinical Trials Unit, London NW1 2DA, UK

Correspondence to:
Correspondence to:
Dr W Qian
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK; wendi.qian{at}ctu.mrc.ac.uk

Background: The incidence of mesothelioma is rising rapidly in the UK. There is no generally accepted standard treatment. The BTS recommends active symptom control (ASC). It is not known whether chemotherapy in addition prolongs survival or provides worthwhile palliation with acceptable toxicity. Palliation as recorded by patients has been fully reported for only two regimens: mitomycin, vinblastine, and cisplatin (MVP), and vinorelbine (N). The BTS and collaborators planned to conduct a phase III randomised trial comparing ASC only, ASC+MVP, and ASC+N in 840 patients with survival as the primary outcome measure. The aim of the present study was to assess the acceptability of the trial design to patients and the suitability of two standard quality of life (QL) questionnaires for mesothelioma.

Methods: Collaborating centres registered all new patients with mesothelioma. Those eligible and giving informed consent completed EORTC QLQ-C30+LC13 and FACT-L QL questionnaires and were randomised between all three or any two of (1) ASC only, (2) ASC+4 cycles of MVP, and (3) ASC+12 weekly doses of N.

Results: During 1 year, 242 patients were registered of whom 109 (45%) were randomised (55% of the 197 eligible patients). Fifty two patients from 20 centres were randomised to an option including ASC only. This translates into a rate of 312 per year from 60 centres interested in collaborating in the phase III trial. The EORTC QL questionnaire was superior to FACT-L in terms of completeness of data and patient preference. Clinically relevant palliation was achieved with ASC.

Conclusion: The planned phase III trial is feasible.

Keywords: mesothelioma; randomised trial; chemotherapy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bottomley, A., Coens, C., Efficace, F., Gaafar, R., Manegold, C., Burgers, S., Vincent, M., Legrand, C., van Meerbeeck, J. P. (2007). Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma. JCO 25: 5770-5776 [Abstract] [Full Text]  
• British Thoracic Society Standards of Care Committ, (2007). BTS statement on malignant mesothelioma in the UK, 2007. Thorax 62: ii1-ii19 [Full Text]  
• Ceresoli, G. L., Gridelli, C., Santoro, A. (2007). Multidisciplinary Treatment of Malignant Pleural Mesothelioma. The Oncologist 12: 850-863 [Abstract] [Full Text]  
• Aelony, Y. (2006). Staging in Malignant Mesothelioma. Ann. Thorac. Surg. 82: 2337-2337 [Full Text]  
• Bottomley, A., Gaafa, R., Manegold, C., Burgers, S., Coens, C., Legrand, C., Vincent, M., Giaccone, G., Van Meerbeeck, J. (2006). Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. JCO 24: 1435-1442 [Abstract] [Full Text]  
• O'Brien, M. E. R., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., Ashley, S., Rowell, N., Sayer, R. (2006). A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17: 270-275 [Abstract] [Full Text]  
• van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., Giaccone, G. (2005). Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. JCO 23: 6881-6889 [Abstract] [Full Text]  
• Steele, J. P. C., Klabatsa, A. (2005). Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16: 345-351 [Abstract] [Full Text]  
• Fennell, D. A., Parmar, A., Shamash, J., Evans, M. T., Sheaff, M. T., Sylvester, R., Dhaliwal, K., Gower, N., Steele, J., Rudd, R. (2005). Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials. JCO 23: 184-189 [Abstract] [Full Text]